Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma
Ergomed is proud to have contributed to a significant breakthrough in oncology through the successful delivery of the IT-MATTERS study, one of the largest clinical trials ever conducted globally in Head and Neck Squamous Cell Carcinoma (SCCHN). The study evaluated the use of neoadjuvant Leukocyte Interleukin Injection (LI) immunotherapy in low-risk, locally advanced SCCHN and demonstrated a meaningful improvement in overall survival.
Co-authored by Dr. Dusan Markovic, Ergomed’s Vice President of Global Medical Affairs, this research highlights the potential of immunotherapy to address long-standing gaps in treatment outcomes for this patient population.